A major clinical trial has found that the risk of early menopause in young women with breast cancer can be dramatically reduced by adding a drug called goserelin to the chemotherapy regimen. It was also revealed that women who took this drug and wanted to have children were more likely to get pregnant and deliver a healthy baby.
Goserelin (trade name, Zoladex®) is similar to a natural hormone made by the body. This drug is FDA-approved for prostate cancer, certain benign gynecological disorders, and certain breast cancers and the overall purpose of goserlin is to temporarily put the ovaries “at rest” during chemotherapy.
“We found that, in addition to reducing the risk of early menopause, and all of the symptoms that go along with menopause, goserelin was very safe and may even improve survival,” Kathy Albain, MD, of Loyola University Medical Center is senior author of the study said. “I think these findings are going to change our clinical practice.”
“Premenopausal women beginning chemotherapy for early breast cancer should consider this new option to prevent premature ovarian failure,” Albain and colleagues concluded.
Results of this study were released during the 2014 American Society of Clinical Oncology 50th Annual Meeting in Chicago.
The clinical trial is named “Prevention of Early Menopause Study (POEMS) S0230.” It is sponsored by SWOG national cancer research cooperative group, along with SWOG’s collaborating groups, including the International Breast Cancer Study Group, Eastern Cooperative Oncology Group and the Alliance for Clinical Trials in Oncology. First author is Halle C.F. Moore, MD, of the Cleveland Clinic. The study was funded in part by the National Cancer Institute.
Sorry, the comment form is closed at this time.